Role of miR-182 in cardiovascular and cerebrovascular diseases

Gaiqin Pei; Li Chen; Yang Wang; Chengqi He; Chenying Fu; Quan Wei

doi:10.3389/fcell.2023.1181515

Role of miR-182 in cardiovascular and cerebrovascular diseases

Front Cell Dev Biol. 2023 May 9:11:1181515. doi: 10.3389/fcell.2023.1181515. eCollection 2023.

Authors

Gaiqin Pei^{1

2}, Li Chen³, Yang Wang^{1

2}, Chengqi He^{1

2}, Chenying Fu^{4

5}, Quan Wei^{1

2}

Affiliations

¹ Department of Rehabilitation Medicine and Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, China.
³ Department of Rehabilitation, Chengdu Fifth People's Hospital, Chengdu, Sichuan, China.
⁴ National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
⁵ Aging and Geriatric Mechanism Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Abstract

The treatment of cardiovascular and cerebrovascular diseases have undergone major advances in recent decades, allowing for a more effective prevention of cardiovascular and cerebrovascular events. However, cardiac and cerebral atherothrombotic complications still account for substantial morbidity and mortality worldwide. Novel therapeutic strategies are critical to improve patient outcomes following cardiovascular diseases. miRNAs are small non-coding RNAs, that regulate gene expression. Here, we discuss the role of miR-182 in regulating myocardial proliferation, migration, hypoxia, ischemia, apoptosis and hypertrophy in atherosclerosis, CAD, MI, I/R injury, organ transplant, cardiac hypertrophy, hypertension, heart failure, congenital heart disease and cardiotoxicity. Besides, we also summarize the current progress of miR-182 therapeutics in clinical development and discuss challenges that will need to be overcome to enter the clinic for patients with cardiac disease.

Keywords: atherosclerosis; cardiovascular and cerebrovascular diseases; heart failure; ischemia/reperfusion (I/R) injury; ischemic stroke; mesenchymal stromal cells; miR-182; myocardial ischemia.

Publication types

Review

Grants and funding

The study was funded by the National Key R&D Program of China (Grant No. 2020YFC2008502) and the 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.